Ifosfamide-induced nephrotoxicity in oncological patients
INTRODUCTION: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage.
AREAS COVERED: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide.
EXPERT OPINION: Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Expert review of anticancer therapy - 24(2024), 1-2 vom: 13. Jan., Seite 5-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quiroz-Aldave, Juan Eduardo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Alkylating |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737140.2023.2290196 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36523012X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36523012X | ||
| 003 | DE-627 | ||
| 005 | 20240214232947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737140.2023.2290196 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM36523012X | ||
| 035 | |a (NLM)38031874 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quiroz-Aldave, Juan Eduardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ifosfamide-induced nephrotoxicity in oncological patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage | ||
| 520 | |a AREAS COVERED: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide | ||
| 520 | |a EXPERT OPINION: Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fanconi syndrome | |
| 650 | 4 | |a Ifosfamide | |
| 650 | 4 | |a drug-related side effects and adverse reactions | |
| 650 | 4 | |a neoplasms | |
| 650 | 4 | |a nephrogenic diabetes insipidus | |
| 650 | 7 | |a Ifosfamide |2 NLM | |
| 650 | 7 | |a UM20QQM95Y |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Alkylating |2 NLM | |
| 700 | 1 | |a Durand-Vásquez, María Del Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Chávez-Vásquez, Freddy Shanner |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Angulo, Alexandra Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzáles-Saldaña, Sonia Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalde-Loyola, Carlos César |e verfasserin |4 aut | |
| 700 | 1 | |a Coronado-Arroyo, Julia Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Zavaleta-Gutiérrez, Francisca Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Concepción-Urteaga, Luis Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Haro-Varas, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Concepción-Zavaleta, Marcio José |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d 2001 |g 24(2024), 1-2 vom: 13. Jan., Seite 5-14 |w (DE-627)NLM11982020X |x 1744-8328 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1-2 |g day:13 |g month:01 |g pages:5-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737140.2023.2290196 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1-2 |b 13 |c 01 |h 5-14 | ||